|
|
|
| home > news > detailed info |
|
|
 INDUSTRY NEWS AND PRESS RELEASES |
Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an ‘Off-The-Shelf’ Cancer Immunotherapy Developed Using Nouscom’s Proprietary Viral Vector Platform |
 |
|
VAC85135 is a novel clinical candidate developed by Nouscom and Janssen under a multi-project agreement
BASEL, Switzerland – 17th May 2022 - Nouscom, a clinical stage immuno-oncology company developing both off-the-shelf and personalized cancer neoantigen immunotherapies, today announced that Janssen Research & Development, LLC (Janssen) received U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) candidate VAC85135, an off-the-shelf, viral vector-based cancer vaccine for an oncologic indication. VAC85135 has been exclusively licensed to Janssen.
VAC85135 is based on Nouscom’s proprietary viral vector platform and is the first vaccine candidate to advance to this stage under a multi-project agreement with Janssen. Nouscom and Janssen have collaborated on the design and specific product research, with Nouscom accountable for process development activities and GMP manufacturing for VAC85135.
Under the terms of the agreement, Janssen has sole responsibility for clinical development of VAC85135. Financial terms, including individual product-specific upfront payments, potential development and commercial milestones, and future tiered royalties remain confidential.
Dr. Marina Udier, Chief Executive Officer of Nouscom, said, “We are very excited about Janssen’s IND clearance of VAC85135, the result of a long-standing and productive collaboration. This is another important milestone for Nouscom, the first licensed program, and the third clinical candidate after NOUS-209 and NOUS-PEV, to emerge from our immunologically potent viral vector platform”.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Fujifilm Invests $188 Million in New Cell Culture Media Manufacturing Facility
TOKYO, November 22, 2022 – FUJIFILM Corporation (President and
CEO, Representative Director: Teiichi Goto) today announced a $188
million investment to establish a cell culture media manufacturing
facility in Research Triangle Park (RTP), North Carolina, USA. The new
site will be operated by FUJIFILM Irvine Scientific, Inc., a subsidiary
of FUJIFILM Corporation, and a world leader in the development and
manufacture of advanced cell culture solutions for life science
research, bioproduction, cell therapy manufacturing, and medical
applications. The new facility is planned to ensure that FUJIFILM Irvine
Scientific can meet increasing market demands for high quality cell
culture media solutions.
More info >> |
|
 |
White Papers |
 |
|
Clinical Trial-Specific Travel Programs as a Patient Retention Tool
For many patients, participating in a clinical trial is a major endeavor. Depending on the protocol requirements, study visits can be exhausting. There are a number of reasons why a patient may choose to participate in a trial only to drop out. Conversely, there are several approaches to proactively try to prevent this from happening. There are various methods professionals implement for patient retention. This white paper explores patient travel services as one patient retention strategy.
More info >> |
|
|
